JOINN - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

assumes no liability for any loss arising out of or in reliance upon the whole or any part of the contents. Ren.

JOINN LABORATORIES (CHINA) CO., LTD.

Beijing Zhaoyan New Drug Research Center Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China) 6127 (Stock code: ) Overseas regulatory announcement

This announcement is made by Beijing Zhaoyan New Drug Research Center Co., Ltd. (the "Company") pursuant to a Hong Kong joint transaction 13.10B made in accordance with Article 1 of the Rules Governing the Listing of Securities of Limited by Share Ltd.

The announcement published by the Company on the website of the Shanghai Stock Exchange is set out below for reference only.

By order of the board of directors Beijing Zhaoyan New Drug Research Center Co., Ltd.

Feng Yuxia Chairman

2026 3 31 Beijing, China, year month day

As at the date of this announcement, the Board of Directors includes Ms. Feng Yuxia, Chairman and Executive Director, and Mr. Gao Dapeng, Executive Director. Sheng, Ms. Sun Yunxia, Mr. Gu Jingliang and Ms. Luo Xi, independent non-executive directors Mr. Zhang Fan and Yang Changyun Mr. Yang Fuquan and Mr. Ying Fangtian, and employee director Ms. Li Ye.

Securities code: 603127 Securities abbreviation: Zhaoyan New Drug Announcement number: 2026-016

Beijing Zhaoyan New Drug Research Center Co., Ltd.

Announcement on abnormal stock trading fluctuations

The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements.

statements or major omissions, and shall bear individual and joint liability for the authenticity, accuracy and completeness of its contents.

Important content reminder:

 Beijing Zhaoyan New Drug Research Center Co., Ltd. (hereinafter referred to as the "Company") stock will be released in 2026 On March 27, March 30 and March 31 of the year, the closing price increases deviated from the value for three consecutive trading days.

Total exceeds 20%. According to the relevant provisions of the "Shanghai Stock Exchange Trading Rules", stocks

Abnormal trading fluctuations.

 After the company’s self-examination and written consultation with the company’s controlling shareholders and actual controllers, as of the disclosure date of this announcement,

The company and its controlling shareholders and actual controllers confirm that there are no major information that should be disclosed but has not been disclosed. interest.

 Investors are advised to pay attention to the risks of secondary market transactions, make rational decisions, and invest prudently.

1. Specific circumstances of abnormal stock trading fluctuations

The company's stock closed for three consecutive trading days on March 27, March 30, and March 31, 2026.

The cumulative price deviation exceeds 20%. According to the relevant provisions of the "Shanghai Stock Exchange Trading Rules", It is a situation of abnormal fluctuations in stock trading.

2. Relevant situations that the company pays attention to and verifies

In view of the abnormal fluctuations in the company's stock trading, the company has verified the relevant matters and will now describe the relevant situation.

The explanation is as follows:

(1) Production and operation conditions After self-examination, the company’s current production and operation activities are normal, and there have been no major changes in the internal and external operating environment.

There is no major information that should be disclosed but has not been disclosed that would affect the abnormal fluctuations in the company's stock trading price.

(2) Major events

After self-examination by the company and written consultation with controlling shareholders and actual controllers, as of the date of this announcement, there are no

There are no major matters that affect abnormal fluctuations in the company's stock trading price, and there are no matters that the company should disclose but fails to disclose.

major information, including but not limited to major asset restructuring, share issuance, acquisition, debt restructuring, business reorganization

Group formation, asset divestiture, asset injection, share repurchase, bankruptcy reorganization, introduction of strategic investors and other major matters.

(3) Media reports, market rumors, and hot concepts The Company has not found any media reports or market rumors that require clarification or response, and the Company has not found any other possible

Major events that have a greater impact on the company's stock price.

(4) Other price-sensitive information

After verification by the company, no controlling shareholders, actual controllers, directors, and senior managers of the company were found to be involved in the company.

The situation of buying and selling the company’s stock during the period of abnormal stock trading fluctuations. 3. Related risk warnings

The company's stock closed within three consecutive trading days on March 27, March 30 and March 31, 2026.

The cumulative deviation of the stock price increase exceeds 20%. The company's stock price has increased significantly in the short term. Investors are kindly requested to pay attention.

Be aware of secondary market transaction risks, make rational decisions, and invest prudently.

All information of the company is disclosed in the designated information disclosure media "Shanghai Securities News" and the website of the Shanghai Stock Exchange. (www.sse.com.cn) shall prevail. Investors are kindly requested to invest rationally and pay attention to investment risks.

4. Statement of the Board of Directors

The company's board of directors confirms that as of the disclosure date of this announcement, the company has no

Matters that should be disclosed but have not been disclosed according to relevant provisions such as the Stock Listing Rules or the planning and business related to such matters

negotiations, intentions, agreements, etc.; the board of directors has not been informed of any relevant matters in accordance with the "Stock Listing Rules of the Shanghai Stock Exchange" Things that should be disclosed according to relevant regulations but are not disclosed may have a greater impact on the trading prices of the company's stocks and their derivatives.

information; there is no need to correct or supplement the information previously disclosed by the company.

Announcement is hereby made.

Beijing Zhaoyan New Drug Research Center Co., Ltd. April 1, 2026